Drug development


Deloitte found that the average cost of developing a new drug among the top 20 global biopharmas it studied rose 15% ($298 million) last year, to approximately $2.3 billion. That figure includes the average cost of developing a candidate from discovery through clinical trials to the market.

Many biopharmaceutical companies are using AI to speed up drug development. For example, machine-learning models are trained using information about the protein or amino-acid sequence or 3D structure of previous drug candidates, and about properties of interest.

Comments

Popular posts from this blog

Perplexity

Aphorisms: AI

DeepAI's Austen on China